Locations:
SearchImmunotherapy’s impact is increasing
As soon as a year from now, look for a “completely different paradigm” in the care of squamous non-small cell lung cancer, says Cleveland Clinic medical oncologist James Stevenson, MD. Dr. Stevenson discussed his outlook in detail at the recent 2016 OncLive State of the Science Summit on Metastatic Non–Small Cell Lung Cancer.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
What changes to expect? Immunotherapy moves to the frontline while chemotherapy shifts to a second-line treatment. Read the entire Q&A with Dr. Stevenson.
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients